# JAMA Oncology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/jama-oncology/

## Facts

| Field | Value |
| --- | --- |
| Citations | 269,301 |
| h-index | 246 |
| Homepage | https://jamanetwork.com/journals/jamaoncology |
| Open Access | false |
| ISSN-L | 2374-2437 |
| ISSNs | 2374-2437,2374-2445 |
| OpenAlex ID | https://openalex.org/S2756165422 |
| Publisher | American Medical Association |
| Works | 4,858 |

## Journal papers

Showing 12 of 102.

- [Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015](https://scholariq.org/papers/global-regional-and-national-cancer-incidence-mortality-years-of-life-lost-years/)
- [Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States](https://scholariq.org/papers/trends-in-the-incidence-prevalence-and-survival-outcomes-in-patients-with/)
- [The Global Burden of Cancer 2013](https://scholariq.org/papers/the-global-burden-of-cancer-2013/)
- [Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017](https://scholariq.org/papers/global-regional-and-national-cancer-incidence-mortality-years-of-life-lost-years-2/)
- [Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019](https://scholariq.org/papers/cancer-incidence-mortality-years-of-life-lost-years-lived-with-disability-and/)
- [Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma](https://scholariq.org/papers/nomenclature-revision-for-encapsulated-follicular-variant-of-papillary-thyroid/)
- [Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer](https://scholariq.org/papers/outcomes-of-observation-vs-stereotactic-ablative-radiation-for-oligometastatic/)
- [Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/association-of-the-lung-immune-prognostic-index-with-immune-checkpoint-inhibitor/)
- [Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue](https://scholariq.org/papers/comparison-of-pharmaceutical-psychological-and-exercise-treatments-for-cancer/)
- [Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials](https://scholariq.org/papers/treatment-related-adverse-events-of-pd-1-and-pd-l1-inhibitors-in-clinical-trials/)
- [Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050](https://scholariq.org/papers/estimates-and-projections-of-the-global-economic-cost-of-29-cancers-in-204/)
- [Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/quantitative-assessment-of-the-heterogeneity-of-pd-l1-expression-in-non-small/)

## Journal top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.